Scott M. Cheney, MD, reviews the background and practical application of minimally-invasive surgical therapies and definitive therapies for benign prostatic hyperplasia (BPH). He then discusses patient selection for these therapy options based on recommendations, level of evidence, and comparative outcomes.
Read More
Sigrid V. Carlsson, MD, PhD, MPH discusses the psychology, history, and practical application of shared decision making. She then provides recommendations for clinicians counseling patients deciding whether or not to undergo PSA screening and if they should go on active surveillance.
Read More
Matt T. Rosenberg, MD, discusses treating of lower urinary tract symptoms (LUTS) through a framework of inhibiting overproduction of urine by the kidneys. In this dual-presentation, he describes behavioral modifications as well as pharmacologic agents for the management of overactive bladder (OAB) and nocturia.
Read More
Dr. Phillip J. Koo, MD, discusses advanced tools such as multi-parametric MRI and PET/CT for prostate cancer imaging, and how they outperform traditional, previously available methods.
Read More
Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.”
Read More